Rajashree Masareddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rajashree Masareddy has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Archana Sidagouda Patil
Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India
9 shared publications - Panchakshari Mallappa Dandagi
Department of Pharmaceutics, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi, India
2 shared publications A. Kokate
Department of Pharmaceutics, College of Pharmacy, KLE University, Belgaum-590 010, India
1 shared publication- Anand Panchakshari Gadad
Department of Pharmaceutics, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research Belagavi, Karnataka, India
1 shared publication - Ankita Patil
Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, India
1 shared publication - Bhaskar Kurangi
Department of Pharmaceutics, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Nehru Nagar
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 29 July 2024
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 10 (1) , 1-11
Omega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits
Background: In recent years, public awareness of healthy diets has significantly increased, leading to a rise in the consumption of nutritional supplements. Among these, omega-3 fatty acids have become particularly popular. n − 3 polyunsaturated fatty acids (PUFAs) are widely distributed in marine and terrestrial environments. The primary sources of marine n − 3 fatty acid supplements are oily fish, such as anchovies, sardines and mackerel. Recently, they have drawn considerable attention for their potential therapeutic benefits in treating a range of illnesses, including cancer, neurological disorders, cardiovascular diseases, immunological and reproductive diseases, respectively. Main text: This study explores the many activities of n − 3 PUFAs, highlighting their importance in cellular processes that include signaling pathways, cell membrane integrity and structural maintenance. These fatty acids significantly regulate important physiological functions including the neurological system, blood pressure control, hematopoiesis, glucose metabolism and inflammatory responses. The latter highlights the wide therapeutic range of n − 3 PUFAs is especially notable considering the implications for controlling inflammatory disorders. Furthermore, the chemistry and dietary sources of omega-3 fatty acids are clarified in this review, which also sheds light on the complex molecular pathways that support the therapeutic efficacy of these fats and their bioavailability. The most recent information on the FDA's approval of omega-3 oils for use in formulation development highlights the compounds' adaptability and potential influence on the development of novel medications. Conclusion: A thorough analysis of omega-3 polyunsaturated fatty acids reveals both their remarkable therapeutic potential against a variety of diseases and their essential place in a normal diet. This study adds to the increasing amount of data that supports the use of n − 3 PUFAs in preventative and therapeutic approaches that are meant to improve human health and well-being by clarifying their mechanisms of action and emphasizing their applicability in formulation and development.
- 29 July 2024
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 10 (1) , 1-11
Top Cited PapersOpen AccessOmega-3 fatty acids: a comprehensive scientific review of their sources, functions and health benefits
Background: In recent years, public awareness of healthy diets has significantly increased, leading to a rise in the consumption of nutritional supplements. Among these, omega-3 fatty acids have become particularly popular. n − 3 polyunsaturated fatty acids (PUFAs) are widely distributed in marine and terrestrial environments. The primary sources of marine n − 3 fatty acid supplements are oily fish, such as anchovies, sardines and mackerel. Recently, they have drawn considerable attention for their potential therapeutic benefits in treating a range of illnesses, including cancer, neurological disorders, cardiovascular diseases, immunological and reproductive diseases, respectively. Main text: This study explores the many activities of n − 3 PUFAs, highlighting their importance in cellular processes that include signaling pathways, cell membrane integrity and structural maintenance. These fatty acids significantly regulate important physiological functions including the neurological system, blood pressure control, hematopoiesis, glucose metabolism and inflammatory responses. The latter highlights the wide therapeutic range of n − 3 PUFAs is especially notable considering the implications for controlling inflammatory disorders. Furthermore, the chemistry and dietary sources of omega-3 fatty acids are clarified in this review, which also sheds light on the complex molecular pathways that support the therapeutic efficacy of these fats and their bioavailability. The most recent information on the FDA's approval of omega-3 oils for use in formulation development highlights the compounds' adaptability and potential influence on the development of novel medications. Conclusion: A thorough analysis of omega-3 polyunsaturated fatty acids reveals both their remarkable therapeutic potential against a variety of diseases and their essential place in a normal diet. This study adds to the increasing amount of data that supports the use of n − 3 PUFAs in preventative and therapeutic approaches that are meant to improve human health and well-being by clarifying their mechanisms of action and emphasizing their applicability in formulation and development.
- 29 February 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (4) , 253-266
Exploring Magnesium Myristate for Its Dual Functionality as a Binder and Lubricant in the Formulation of Tablet
Purpose: To explore ‘magnesium myristate’ for its dual functionality as a lubricant and binder in the formulation of tablets. Methods: Using (DoE), tablet formulations using magnesium myristate and...
- 29 February 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (4) , 253-266
Exploring Magnesium Myristate for Its Dual Functionality as a Binder and Lubricant in the Formulation of Tablet
Purpose: To explore ‘magnesium myristate’ for its dual functionality as a lubricant and binder in the formulation of tablets. Methods: Using (DoE), tablet formulations using magnesium myristate and...
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 12 (1) , 79-89
Fabrication, Optimization, and Evaluation of Transdermal Patch: As an Alternative and Effective Transdermal Delivery System for Nebivolol HCl
Background: Nebivolol HCl is a unique third-generation beta blocker that has less oral bioavailability and exhibits various adverse effects like gastrointestinal disturbance and abdominal pain. Objective: This study aimed to formulate and evaluate nebivolol HCl transferosomal transdermal patches to reduce the problems associated with oral delivery of the drug and enhancement of drug permeation through the skin. Methodds: Nebivolol HCl loaded transferosomes were prepared by thin film hydration method. Eight formulations were prepared based on the two independent variables, type of surfactant (Tween 80 and Span 80) and Phospholipid: Edge activator ratio and were evaluated for their vesicle size, PDI, and entrapment efficiency. The optimized formulations were incorporated into transdermal patches, which were evaluated for physicochemical properties, in-vitro and ex-vivo permeation, skin irritancy, and stability studies. Results: The vesicle size of the transferosomes ranged from 49nm to 93nm, and EE% varied from 39% to 79%. Vesicles formed with Span 80 as an edge activator showed smaller vesicle size and greater EE% as compared to Tween 80. Based on the results, TW4 and SP4 were selected as the optimized formulations for further incorporation into the transdermal patches. In-vitro and ex-vivo permeation studies showed permeation in the order F2 > F3 > F1, indicating that transferosomal formulations showed superior permeation of the drug compared to plain Nebivolol HCl patches. Span 80 transferosomes showed a slightly better permeation than Tween 80. Stability studies showed that transferosomes and the transdermal patches demonstrated good stability under proper storage conditions. Conclusion: The study concluded that transferosomal patches of Nebivolol HCl could be used as a potential approach with effective transdermal delivery for the management of hypertension.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Pharmaceutical Nanotechnology
- Vol. 12 (1) , 79-89
Fabrication, Optimization, and Evaluation of Transdermal Patch: As an Alternative and Effective Transdermal Delivery System for Nebivolol HCl
Background: Nebivolol HCl is a unique third-generation beta blocker that has less oral bioavailability and exhibits various adverse effects like gastrointestinal disturbance and abdominal pain. Objective: This study aimed to formulate and evaluate nebivolol HCl transferosomal transdermal patches to reduce the problems associated with oral delivery of the drug and enhancement of drug permeation through the skin. Methodds: Nebivolol HCl loaded transferosomes were prepared by thin film hydration method. Eight formulations were prepared based on the two independent variables, type of surfactant (Tween 80 and Span 80) and Phospholipid: Edge activator ratio and were evaluated for their vesicle size, PDI, and entrapment efficiency. The optimized formulations were incorporated into transdermal patches, which were evaluated for physicochemical properties, in-vitro and ex-vivo permeation, skin irritancy, and stability studies. Results: The vesicle size of the transferosomes ranged from 49nm to 93nm, and EE% varied from 39% to 79%. Vesicles formed with Span 80 as an edge activator showed smaller vesicle size and greater EE% as compared to Tween 80. Based on the results, TW4 and SP4 were selected as the optimized formulations for further incorporation into the transdermal patches. In-vitro and ex-vivo permeation studies showed permeation in the order F2 > F3 > F1, indicating that transferosomal formulations showed superior permeation of the drug compared to plain Nebivolol HCl patches. Span 80 transferosomes showed a slightly better permeation than Tween 80. Stability studies showed that transferosomes and the transdermal patches demonstrated good stability under proper storage conditions. Conclusion: The study concluded that transferosomal patches of Nebivolol HCl could be used as a potential approach with effective transdermal delivery for the management of hypertension.
- 29 January 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (3) , 165-179
Formulation and Evaluation of Itraconazole-Loaded Nanoemulgel for Efficient Topical Delivery to Treat Fungal Infections
Aim: The clinical application of conventional oral dosage form of itraconazole is limited due to its poor bioavailability. The aim of the study was to develop nanoemulgel of Itraconazole for topica... Graphical abstract
- 29 January 2024
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 15 (3) , 165-179
Formulation and Evaluation of Itraconazole-Loaded Nanoemulgel for Efficient Topical Delivery to Treat Fungal Infections
Aim: The clinical application of conventional oral dosage form of itraconazole is limited due to its poor bioavailability. The aim of the study was to develop nanoemulgel of Itraconazole for topica... Graphical abstract
- 18 July 2023
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 14 (7) , 443-458
A Comprehensive Review on Pharmaceutical Excipients
The effectiveness of pharmaceutical drugs depends not only on their active components and manufacturing processes, but also on the role played by pharmaceutical excipients. The traditional definiti... Plain language summary Excipients are matter we add to medicine when we make it. They give the medicine different qualities, like making it easier to dissolve, stick together, or slide smoothly. Bu...
- 18 July 2023
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 14 (7) , 443-458
A Comprehensive Review on Pharmaceutical Excipients
The effectiveness of pharmaceutical drugs depends not only on their active components and manufacturing processes, but also on the role played by pharmaceutical excipients. The traditional definiti... Plain language summary Excipients are matter we add to medicine when we make it. They give the medicine different qualities, like making it easier to dissolve, stick together, or slide smoothly. Bu...
- 1 March 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 20 (3) , 237-249
Current Novel Drug Deliveries for Oral Cancer: A Chronotherapeutic Approach
Oral squamous cell carcinoma is a malignant disease that is causing considerable mortality worldwide. Conventional treatment approaches, like surgery, cause destructive alterations in facial appearance and oral function impairments associated with psychological and social functioning. Chemotherapy exhibits low bioaccessibility of the anticancer drugs, multiple drug resistance, higher dose necessities, which elevate toxicities to the normal cells, low therapeutic index, and non-specific targeting. Radiation therapies significantly affect the well-being of the patient and impair the quality of life. Therefore, chemotherapeutics are developed that can either actively or passively target the carcinomas, reduce the adverse side effect, and improve therapeutic efficacy. Innovations in novel drug delivery systems deliver the drugs to the desired site of action with better treatment approaches with reduced toxicities to the normal cells and improve the health and survival rate of the patient. Cancer chronotherapy enhances the treatment proficiency by administration of the drugs at the best time, considering biological timings to improve the treatment profiles. Chronotherapy provides benefits to the current anticancer therapies, with minimum adverse effects to the healthy cells. This review discusses the risk factors for oral carcinomas, targeted therapy by nanocarriers, nanotechnology approaches, the role of circadian rhythm in the management of oral cancer, and advances in controlled drug delivery.
- 1 March 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Delivery
- Vol. 20 (3) , 237-249
Current Novel Drug Deliveries for Oral Cancer: A Chronotherapeutic Approach
Oral squamous cell carcinoma is a malignant disease that is causing considerable mortality worldwide. Conventional treatment approaches, like surgery, cause destructive alterations in facial appearance and oral function impairments associated with psychological and social functioning. Chemotherapy exhibits low bioaccessibility of the anticancer drugs, multiple drug resistance, higher dose necessities, which elevate toxicities to the normal cells, low therapeutic index, and non-specific targeting. Radiation therapies significantly affect the well-being of the patient and impair the quality of life. Therefore, chemotherapeutics are developed that can either actively or passively target the carcinomas, reduce the adverse side effect, and improve therapeutic efficacy. Innovations in novel drug delivery systems deliver the drugs to the desired site of action with better treatment approaches with reduced toxicities to the normal cells and improve the health and survival rate of the patient. Cancer chronotherapy enhances the treatment proficiency by administration of the drugs at the best time, considering biological timings to improve the treatment profiles. Chronotherapy provides benefits to the current anticancer therapies, with minimum adverse effects to the healthy cells. This review discusses the risk factors for oral carcinomas, targeted therapy by nanocarriers, nanotechnology approaches, the role of circadian rhythm in the management of oral cancer, and advances in controlled drug delivery.
- 26 May 2022
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 13 (5) , 283-294
Formulation, Optimization and Validation of Floating OralIn SituGel of Ivabradine Hydrochloride
Aim: Ivabradine hydrochloride is a hyperpolarized activated channel blocker used for symptomatic treatment of chronic angina pectoris. However, due to its short half-life it is rapidly eliminated f... Graphical abstract
- 26 May 2022
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 13 (5) , 283-294
Formulation, Optimization and Validation of Floating OralIn SituGel of Ivabradine Hydrochloride
Aim: Ivabradine hydrochloride is a hyperpolarized activated channel blocker used for symptomatic treatment of chronic angina pectoris. However, due to its short half-life it is rapidly eliminated f... Graphical abstract
- 19 January 2022
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 17 (4) , 1347-1359
Microsponge Gel Approach to Increase the Stability and Efficacy of Avobenzone as a Sun-Protective Agent
- 19 January 2022
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 17 (4) , 1347-1359
Microsponge Gel Approach to Increase the Stability and Efficacy of Avobenzone as a Sun-Protective Agent
- 28 October 2021
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 18 (5) , 514-549
Exploring the Solvent-Anti-solvent Method of Nanosuspension for Enhanced Oral Bioavailability of Lovastatin
Lovastatin is an antilipidemic drug that belongs to the class of statins that has poor oral bioavailability due to its low solubility and variable dissolution rate. The main aim of this study was to enhance the solubility and dissolution rate of the drug and understand its oral bioavailability. Lovastatin nanosuspension was formulated using a solventanti-solvent method using a probe sonication technique. A nanosuspension was prepared, using hydroxypropyl methylcellulose (HPMC) K15M and pluronic F68 as stabilizers. The formulated nanosuspensions were characterized for particle size, polydispersity index (PDI) zeta potential, surface morphology, and in vitro release rate. Further, an in vivo bioavailability study and stability studies were also performed. Optimized formulation showed a particle size of 127±0.01 nm, a PDI of 0.492±0.001, and a zeta potential of -37.9 mV, which indicates good stability. Morphological study showed that the particles were in the nano range. The drug content was found to be in the range of 73-87%. In vitro release revealed much faster release of the drug in one hour compared to the pure drug and its marketed formulation. In vivo bioavailability study was carried out in Wistar rats, which showed improvement in bioavailability by approximately 2.5 folds compared with the marketed formulation. Stability studies indicated that the optimized formulation F2 was more stable at 4°C±2°C. The prepared lovastatin nanosuspension showed improvement in solubility, dissolution rate, and oral bioavailability compared to the pure drug and its marketed formulation. Hence, lovastatin nanosuspension may be a potentially valuable tool for improving the oral bioavailability of lovastatin.
- 28 October 2021
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 18 (5) , 514-549
Exploring the Solvent-Anti-solvent Method of Nanosuspension for Enhanced Oral Bioavailability of Lovastatin
Lovastatin is an antilipidemic drug that belongs to the class of statins that has poor oral bioavailability due to its low solubility and variable dissolution rate. The main aim of this study was to enhance the solubility and dissolution rate of the drug and understand its oral bioavailability. Lovastatin nanosuspension was formulated using a solventanti-solvent method using a probe sonication technique. A nanosuspension was prepared, using hydroxypropyl methylcellulose (HPMC) K15M and pluronic F68 as stabilizers. The formulated nanosuspensions were characterized for particle size, polydispersity index (PDI) zeta potential, surface morphology, and in vitro release rate. Further, an in vivo bioavailability study and stability studies were also performed. Optimized formulation showed a particle size of 127±0.01 nm, a PDI of 0.492±0.001, and a zeta potential of -37.9 mV, which indicates good stability. Morphological study showed that the particles were in the nano range. The drug content was found to be in the range of 73-87%. In vitro release revealed much faster release of the drug in one hour compared to the pure drug and its marketed formulation. In vivo bioavailability study was carried out in Wistar rats, which showed improvement in bioavailability by approximately 2.5 folds compared with the marketed formulation. Stability studies indicated that the optimized formulation F2 was more stable at 4°C±2°C. The prepared lovastatin nanosuspension showed improvement in solubility, dissolution rate, and oral bioavailability compared to the pure drug and its marketed formulation. Hence, lovastatin nanosuspension may be a potentially valuable tool for improving the oral bioavailability of lovastatin.